Madrigal Pharmaceuticals said that its drug Rezdiffra was approved by the FDA as the first treatment for patients with nonalcoholic steatohepatitis who also have moderate to advanced liver fibrosis. Rezdiffra, which is intended to be used alongside diet and exercise, will become available to patients in April.